ABBV•benzinga•
Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday?
Summary
AbbVie and Xilio partner to develop tumor-activated immunotherapies. Xilio's pipeline includes masked T cell engagers for prostate, gastric, and lung cancers.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 12, 2025 by benzinga